Skip To Content
Do-Youn Oh
Department

1   Hemato Oncology

2   Medical Oncology Center

Specialty

1   Gastic cancer , Pancreatic cancer , Biliary tract cancer , Neuroendocrine tumor , Clinical trial , Clinical trial for drug development

2   Gastic cancer , Pancreatic cancer , Biliary tract cancer , Neuroendocrine tumor , Clinical trial , Clinical trial for drug development

Appointment

Education / Career

Education / Career
Article Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.
Announcements J Clin Oncol. Date of publication 2024
Co-researcher Meric-Bernstam F, Makker V, Oaknin A, Oh DY, Banerjee S, González-Martín A, Jung KH, Ługowska I, Manso L, Manzano A, Melichar B, Siena S, Stroyakovskiy D, Fielding A, Ma Y, Puvvada S, Shire N, Lee JY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/37870536/
Education / Career
Article Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
Announcements N Engl J Med. Date of publication 2023
Co-researcher Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, Kl�mpen HJ, Chang HM, Chen LT, Tabernero J, Oh DY, Mahipal A, Moehler M, Mitchell EP, Komatsu Y, Masuda K, Ahn D, Epstein RS, Halim AB, Fu Y, Salimi T, Wacheck V, He Y, Liu M, Benhadji KA, Bridgewater JA; FOENIX-CCA2 Study Investigators.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36652354/
Education / Career
Article Silmitasertib plus gemcitabine and cisplatin first-line therapy in locally advanced/metastatic cholangiocarcinoma: A Phase 1b/2 study.
Announcements Hepatology. Date of publication 2023
Co-researcher Borad MJ, Bai LY, Richards D, Mody K, Hubbard J, Rha SY, Soong J, McCormick D, Tse E, O'Brien D, Bayat A, Ahn D, Davis SL, Park JO, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36152015/
Education / Career
Article A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03).
Announcements Cancer Res Treat. Date of publication 2023
Co-researcher Lee DW, Keam B, Lee KS, Ahn JH, Sohn J, Ahn JS, Lee MH, Kim JH, Lee KE, Kim HJ, Kim SY, Park YH, Ock CY, Lee KH, Han SW, Kim SB, Im YH, Chung HC, Oh DY, Im SA.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36397238/
Education / Career
Article Combination of chemotherapy and focused ultrasound for the treatment of unresectable pancreatic cancer: a proof-of-concept study.
Announcements Eur Radiol. Date of publication 2023
Co-researcher Lee JY, Oh DY, Lee KH, Lee SH, Lee DH, Kang K, Kang SY, Park DH
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36482217/
Education / Career
Article Napabucasin plus nab-paclitaxel with gemcitabine versus nab-paclitaxel with gemcitabine in previously untreated metastatic pancreatic adenocarcinoma: an adaptive multicentre, randomised, open-label, phase 3, superiority trial.
Announcements EClinicalMedicine. Date of publication 2023
Co-researcher Bekaii-Saab T, Okusaka T, Goldstein D, Oh DY, Ueno M, Ioka T, Fang W, Anderson EC, Noel MS, Reni M, Choi HJ, Goldberg JS, Oh SC, Li CP, Tabernero J, Li J, Foos E, Oh C, Van Cutsem E.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36969338/
Education / Career
Article Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Announcements J Clin Oncol. Date of publication 2023
Co-researcher Tempero MA, Pelzer U, O'Reilly EM, Winter J, Oh DY, Li CP, Tortora G, Chang HM, Lopez CD, Bekaii-Saab T, Ko AH, Santoro A, Park JO, Noel MS, Frassineti GL, Shan YS, Dean A, Riess H, Van Cutsem E, Berlin J, Philip P, Moore M, Goldstein D, Tabernero J, Li M, Ferrara S, Le Bruchec Y, Zhang G, Lu B, Biankin AV, Reni M; APACT Investigators.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36521097/
Education / Career
Article Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study.
Announcements Cancer. Date of publication 2023
Co-researcher Oh DY, Algazi A, Capdevila J, Longo F, Miller W Jr, Chun Bing JT, Bonilla CE, Chung HC, Guren TK, Lin CC, Motola-Kuba D, Shah M, Hadoux J, Yao L, Jin F, Norwood K, Lebellec L.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36748723/
Education / Career
Article Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.
Announcements Oncology (Williston Park). Date of publication 2023
Co-researcher Catenacci DV, Kang YK, Uronis HE, Lee KW, Ng MC, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Oh DY, Yen J, Odegaard JI, Lagow E, Li D, Sun J, Kaminker P, Moore PA, Rosales MK, Park H.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/37104758/
Education / Career
Article Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.
Announcements Cancer Med. Date of publication 2023
Co-researcher Kwon HJ, Park Y, Nam SK, Kang E, Kim KK, Jeong I, Kwak Y, Yoon J, Kim TY, Lee KW, Oh DY, Im SA, Kong SH, Park DJ, Lee HJ, Kim HH, Yang HK, Lee HS.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36916290/
Education / Career
Article Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma.
Announcements Cancers (Basel). Date of publication 2023
Co-researcher Mar N, Zakharia Y, Falcon A, Morales-Barrera R, Mellado B, Duran I, Oh DY, Williamson SK, Gajate P, Arkenau HT, Jones RJ, Teo MY, Turan T, McLaughlin RT, Peltier HM, Chong E, Atluri H, Dean JP, Castellano D.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/37296940/
Education / Career
Article Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
Announcements Oncologist. Date of publication 2023
Co-researcher Ko AH, Kim KP, Siveke JT, Lopez CD, Lacy J, O'Reilly EM, Macarulla T, Manji GA, Lee J, Ajani J, Alsina Maqueda M, Rha SY, Lau J, Al-Sakaff N, Allen S, Lu D, Shemesh CS, Gan X, Cha E, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36940261/
Education / Career
Article Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Announcements Lancet Oncol. Date of publication 2023
Co-researcher Harding JJ, Fan J, Oh DY, Choi HJ, Kim JW, Chang HM, Bao L, Sun HC, Macarulla T, Xie F, Metges JP, Ying J, Bridgewater J, Lee MA, Tejani MA, Chen EY, Kim DU, Wasan H, Ducreux M, Bao Y, Boyken L, Ma J, Garfin P, Pant S; HERIZON-BTC-01 study group.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/37276871/
Education / Career
Article Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers.
Announcements Hepatology. Date of publication 2023
Co-researcher Yoo C, Javle MM, Verdaguer Mata H, de Braud F, Trojan J, Raoul JL, Kim JW, Ueno M, Lee CK, Hijioka S, Cubillo A, Furuse J, Azad N, Sato M, Vugmeyster Y, Machl A, Bajars M, Bridgewater J, Oh DY, Borad MJ.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36999533/
Education / Career
Article Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
Announcements J Clin Oncol. Date of publication 2023
Co-researcher Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/37751561/
Education / Career
Article Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Announcements Future Oncol. Date of publication 2023
Co-researcher Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, Żotkiewicz M, Kurland JF, Cohen G, Valle JW.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/37746835/
Education / Career
Article Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
Announcements JAMA Oncol. Date of publication 2023
Co-researcher Kim TW, Bedard PL, LoRusso P, Gordon MS, Bendell J, Oh DY, Ahn MJ, Garralda E, D'Angelo SP, Desai J, Hodi FS, Wainberg Z, Delord JP, Cassier PA, Cervantes A, Gil-Martin M, Wu B, Patil NS, Jin Y, Hoang T, Mendus D, Wen X, Meng R, Cho BC.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/37768658/
Education / Career
Article Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial.
Announcements Lancet Oncol. Date of publication 2023
Co-researcher Rha SY, Oh DY, Ya�ez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, Fern�ndez MG, Li J, Lowery MA, �il T, Cruz FM, Qin S, Luo S, Pan H, Wainberg ZA, Yin L, Bordia S, Bhagia P, Wyrwicz LS; KEYNOTE-859 investigators.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/37875143/
Education / Career
Article Ibrutinib combination therapy for advanced gastrointestinal and genitourinary tumours: results from a phase 1b/2 study.
Announcements BMC Cancer. Date of publication 2023
Co-researcher Oh DY, Maqueda MA, Quinn DI, O'Dwyer PJ, Chau I, Kim SY, Duran I, Castellano D, Berlin J, Mellado B, Williamson SK, Lee KW, Marti F, Mathew P, Saif MW, Wang D, Chong E, Hilger-Rolfe J, Dean JP, Arkenau HT.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/37919668/
Education / Career
Article Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2-Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study.
Announcements J Clin Oncol. Date of publication 2023
Co-researcher Nakamura Y, Mizuno N, Sunakawa Y, Canon JL, Galsky MD, Hamilton E, Hayashi H, Jerusalem G, Kim ST, Lee KW, Kankeu Fonkoua LA, Monk BJ, Nguyen D, Oh DY, Okines A, O'Malley DM, Pohlmann P, Reck M, Shin SJ, Sudo K, Takahashi S, Van Marcke C, Yu EY, Groisberg R, Ramos J, Tan S, Stinchcombe TE, Bekaii-Saab T.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/37751561/
Education / Career
Article Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy.
Announcements J Hepatobiliary Pancreat Sci. Date of publication 2023
Co-researcher Lee M, Kang JS, Kim H, Kwon W, Lee SH, Ryu JK, Kim YT, Oh DY, Chie EK, Jang JY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34581022/
Education / Career
Article Recent Progress in Immunotherapy for Gastric Cancer.
Announcements J Gastric Cancer. Date of publication 2023
Co-researcher Yoon J, Kim TY, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36751000/
Education / Career
Article Exploration of predictors of benefit from nivolumab monotherapy for patients with pretreated advanced gastric and gastroesophageal junction cancer: post hoc subanalysis from the ATTRACTION-2 study.
Announcements Gastric Cancer. Date of publication 2022
Co-researcher Kang YK, Morita S, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Chen LT, Boku N.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34480657/
Education / Career
Article Varlitinib plus capecitabine in second-line advanced biliary tract cancer: a randomized, phase II study (TreeTopp).
Announcements ESMO Open. Date of publication 2022
Co-researcher Javle MM, Oh DY, Ikeda M, Yong WP, Hsu K, Lindmark B, McIntyre N, Firth C.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34922298/
Education / Career
Article Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial.
Announcements Lancet Oncol. Date of publication 2022
Co-researcher Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, Chung IJ, Yamaguchi K, Kato K, Sym SJ, Kadowaki S, Tsuji K, Chen JS, Bai LY, Oh SY, Choda Y, Yasui H, Takeuchi K, Hirashima Y, Hagihara S, Boku N.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/35030335/
Education / Career
Article Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer.
Announcements Cancer Res Treat. Date of publication 2022
Co-researcher Seo HR, Nam AR, Bang JH, Oh KS, Kim JM, Yoon J, Kim TY, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34352995/
Education / Career
Article Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma.
Announcements Eur J Endocrinol. Date of publication 2022
Co-researcher Waguespack SG, Drilon A, Lin JJ, Brose MS, McDermott R, Almubarak M, Bauman J, Casanova M, Krishnamurthy A, Kummar S, Leyvraz S, Oh DY, Park K, Sohal D, Sherman E, Norenberg R, Silvertown JD, Brega N, Hong DS, Cabanillas ME.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/35333737/
Education / Career
Article Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16).
Announcements Gastric Cancer. Date of publication 2022
Co-researcher Kim BJ, Jee HJ, Rha SY, Han HS, Ryu MH, Park SH, Kim JG, Bae WK, Lee KW, Oh DY, Byun JH, Kim DS, Suh YJ, An H, Zang DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/35015188/
Education / Career
Article The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial.
Announcements Mol Oncol. Date of publication 2022
Co-researcher Triulzi T, Bianchini G, Di Cosimo S, Pienkowski T, Im YH, Bianchi GV, Galbardi B, Dugo M, De Cecco L, Tseng LM, Liu MC, Bermejo B, Semiglazov V, Viale G, de la Haba-Rodriguez J, Oh DY, Poirier B, Valagussa P, Gianni L, Tagliabue E.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34816585/
Education / Career
Article Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
Announcements Lancet Gastroenterol Hepatol. Date of publication 2022
Co-researcher Oh DY, Lee KH, Lee DW, Yoon J, Kim TY, Bang JH, Nam AR, Oh KS, Kim JM, Lee Y, Guthrie V, McCoon P, Li W, Wu S, Zhang Q, Rebelatto MC, Kim JW.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/35278356/
Education / Career
Article Health-related quality of life in patients treated with pembrolizumab for microsatellite instability-high/mismatch repair-deficient advanced solid tumours: Results from the KEYNOTE-158 study.
Announcements Eur J Cancer. Date of publication 2022
Co-researcher Maio M, Amonkar MM, Norquist JM, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Bariani GM, De Jesus Acosta A, Doi T, Longo F, Miller WH Jr, Oh DY, Gottfried M, Wang R, Norwood K, Marabelle A.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/35588692/
Education / Career
Article Tolerability and efficacy of durvalumab, either as monotherapy or in combination with tremelimumab, in patients from Asia with advanced biliary tract, esophageal, or head-and-neck cancer.
Announcements Cancer Med. Date of publication 2022
Co-researcher Doki Y, Ueno M, Hsu CH, Oh DY, Park K, Yamamoto N, Ioka T, Hara H, Hayama M, Nii M, Komuro K, Sugimoto M, Tahara M.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/35611499/
Education / Career
Article Evaluation of pembrolizumab monotherapy in patients with previously treated advanced salivary gland carcinoma in the phase 2 KEYNOTE-158 study.
Announcements Eur J Cancer. Date of publication 2022
Co-researcher Even C, Delord JP, Price KA, Nakagawa K, Oh DY, Burge M, Chung HC, Doi T, Fakih M, Takahashi S, Yao L, Jin F, Norwood K, Hansen AR.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/35777186/
Education / Career
Article A synthetic lethal strategy using PARP and ATM inhibition for overcoming trastuzumab resistance in HER2-positive cancers.
Announcements Oncogene. Date of publication 2022
Co-researcher Oh KS, Nam AR, Bang JH, Seo HR, Kim JM, Yoon J, Kim TY, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/35798878/
Education / Career
Article Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.
Announcements Ann Oncol. Date of publication 2022
Co-researcher Maio M, Ascierto PA, Manzyuk L, Motola-Kuba D, Penel N, Cassier PA, Bariani GM, De Jesus Acosta A, Doi T, Longo F, Miller WH, Oh DY, Gottfried M, Xu L, Jin F, Norwood K, Marabelle A.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/35680043/
Education / Career
Article Margetuximab with retifanlimab as first-line therapy in HER2+/PD-L1+ unresectable or metastatic gastroesophageal adenocarcinoma: MAHOGANY cohort A.
Announcements ESMO Open. Date of publication 2022
Co-researcher Catenacci DVT, Kang YK, Yoon HH, Shim BY, Kim ST, Oh DY, Spira AI, Ulahannan SV, Avery EJ, Boland PM, Chao J, Chung HC, Gardner F, Klempner SJ, Lee KW, Oh SC, Peguero J, Sonbol MB, Shen L, Moehler M, Sun J, Li D, Rosales MK, Park H.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36029651/
Education / Career
Article Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Announcements J Clin Oncol. Date of publication 2022
Co-researcher Kindler HL, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Alg�l H, O'Reilly EM, Bordia S, McGuinness D, Cui K, Locker GY, Golan T.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/35834777/
Education / Career
Article Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study.
Announcements Lancet Oncol. Date of publication 2022
Co-researcher Meric-Bernstam F, Beeram M, Hamilton E, Oh DY, Hanna DL, Kang YK, Elimova E, Chaves J, Goodwin R, Lee J, Nabell L, Rha SY, Mayordomo J, El-Khoueiry A, Pant S, Raghav K, Kim JW, Patnaik A, Gray T, Davies R, Ozog MA, Woolery J, Lee KW.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/36400106/
Education / Career
Article Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer
Announcements NEJM Evid. Date of publication 2022
Co-researcher Do-Youn Oh, Aiwu Ruth He, Shukui Qin, Li-Tzong Chen, Takuji Okusaka, Arndt Vogel, Jin Won Kim, Thatthan Suksombooncharoen, Myung Ah Lee, Masayuki Kitano, Howard Burris, Mohamed Bouattour, Suebpong Tanasanvimon, Mair�ad G. McNamara, Renata Zaucha, Antonio Avallone, Benjamin Tan, Juan Cundom, Choong-kun Lee, Hidenori Takahashi, Masafumi Ikeda, Jen-Shi Chen, Julie Wang, Mallory Makowsky, Nana Rokutanda, Philip He, John F. Kurland, Gordon Cohen and Juan W. Valle for the TOPAZ-1 Investigators*
Education / Career
Article Prospective evaluation of metabolic intratumoral heterogeneity in patients with advanced gastric cancer receiving palliative chemotherapy.
Announcements Sci Rep. Date of publication 2021
Co-researcher Yoo SH, Kang SY, Yoon J, Kim TY, Cheon GJ, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33436659/
Education / Career
Article Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.
Announcements JAMA Oncol. Date of publication 2021
Co-researcher Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DVT, Borad MJ, Bridgewater JA, Harris WP, Murphy AG, Oh DY, Whisenant JR, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Chamberlain CX, Aguado-Fraile E, Choe S, Wu B, Liu H, Gliser C, Pandya SS, Valle JW, Abou-Alfa GK.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34554208/
Education / Career
Article Role of adjuvant radiotherapy in extrahepatic bile duct cancer: A multicenter retrospective study (Korean Radiation Oncology Group 18-14).
Announcements Eur J Cancer. Date of publication 2021
Co-researcher Kim K, Yu JI, Jung W, Kim TH, Seong J, Kim WC, Choi JH, Park Y, Jeong BK, Kim BH, Kim TG, Kim JH, Park HJ, Shin HS, Im JH, Heo JS, Park JO, Jang JY, Oh DY, Woo SM, Lee WJ, Chie EK.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34474218/
Education / Career
Article Evaluation of Minimal Important Difference and Responder Definition in the EORTC QLQ-PAN26 Module for Assessing Health-Related Quality of Life in Patients with Surgically Resected Pancreatic Adenocarcinoma.
Announcements Ann Surg Oncol. Date of publication 2021
Co-researcher Reni M, Braverman J, Hendifar A, Li CP, Macarulla T, Oh DY, Riess H, Tempero M, Lu B, Marcus J, Joshi N, Botteman M, Dueck AC.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33813673/
Education / Career
Article Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study.
Announcements Lancet Oncol. Date of publication 2021
Co-researcher Valle JW, Vogel A, Denlinger CS, He AR, Bai LY, Orlova R, Van Cutsem E, Adeva J, Chen LT, Obermannova R, Ettrich TJ, Chen JS, Wasan H, Girvan AC, Zhang W, Liu J, Tang C, Ebert PJ, Aggarwal A, McNeely SC, Moser BA, Oliveira JM, Carlesi R, Walgren RA, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34592180/
Education / Career
Article The Role of Adjuvant Chemoradiotherapy in Nonhilar Extrahepatic Bile Duct Cancer: A Long-Term Single-Institution Analysis.
Announcements Int J Radiat Oncol Biol Phys. Date of publication 2021
Co-researcher Chang WI, Kim BH, Kang HC, Kim K, Lee KH, Oh DY, Kim H, Kwon W, Jang JY, Chie EK.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34029643/
Education / Career
Article A first-in-human phase I study of TAS0728, an oral covalent binding inhibitor of HER2, in patients with advanced solid tumors with HER2 or HER3 aberrations.
Announcements Invest New Drugs. Date of publication 2021
Co-researcher Piha-Paul SA, Azaro A, Arkenau HT, Oh DY, Galsky MD, Pal SK, Hamada K, He Y, Yamamiya I, Benhadji KA, Hollebecque A.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33774767/
Education / Career
Article Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer.
Announcements Cancer Res Treat. Date of publication 2021
Co-researcher Lee KH, Chie EK, Im SA, Kim JH, Kwon J, Han SW, Oh DY, Jang JY, Kim JS, Kim TY, Bang YJ, Kim SW, Ha SW.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33421976/
Education / Career
Article ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.
Announcements Cancer Lett. Date of publication 2021
Co-researcher Nam AR, Yoon J, Jin MH, Bang JH, Oh KS, Seo HR, Kim JM, Kim TY, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34082024/
Education / Career
Article Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).
Announcements Ther Adv Med Oncol. Date of publication 2021
Co-researcher Han HS, Kim BJ, Jee HJ, Ryu MH, Park SH, Rha SY, Kim JG, Bae WK, Lee KW, Oh DY, Kim IH, Sym SJ, Oh SY, Kim HS, Byun JH, Kim DS, Suh YJ, An H, Zang DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34552667/
Education / Career
Article NTRK- and RET-fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.
Announcements J Clin Invest. Date of publication 2021
Co-researcher Lee YA, Lee H, Im SW, Song YS, Oh DY, Kang HJ, Won JK, Jung KC, Kwon D, Chung EJ, Hah JH, Paeng JC, Kim JH, Choi J, Kim OH, Oh JM, Ahn BC, Wirth LJ, Shin CH, Kim JI, Park YJ.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34237031/
Education / Career
Article WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers.
Announcements Gastric Cancer. Date of publication 2021
Co-researcher Jin MH, Nam AR, Bang JH, Oh KS, Seo HR, Kim JM, Yoon J, Kim TY, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33723720/
Education / Career
Article Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab.
Announcements Gastric Cancer. Date of publication 2021
Co-researcher Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Nishiyama T, Chen LT, Kang YK.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33743112/
Education / Career
Article The NHance� Mutation-Equipped Anti-MET Antibody ARGX-111 Displays Increased Tissue Penetration and Anti-Tumor Activity in Advanced Cancer Patients.
Announcements Biomedicines. Date of publication 2021
Co-researcher Aftimos P, Rolfo C, Rottey S, Barth�l�my P, Borg C, Park K, Oh DY, Kim SW, De Jonge N, Hanssens V, Zwanenpoel K, Molthoff C, Vugts D, Dreier T, Verheesen P, van Dongen GAMS, Jacobs J, Van Rompaey L, Hultberg A, Michieli P, Pauwels P, Fung S, Thibault A, de Haard H, Leupin N, Awada A.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34200749/
Education / Career
Article Comparison of Clinical Outcomes of Borderline Resectable Pancreatic Cancer According to the Neoadjuvant Chemo-Regimens: Gemcitabine versus FOLFIRINOX.
Announcements Gut Liver. Date of publication 2021
Co-researcher Choi YJ, Byun Y, Kang JS, Kim HS, Han Y, Kim H, Kwon W, Oh DY, Paik WH, Lee SH, Ryu JK, Kim YT, Lee K, Kim H, Chie EK, Jang JY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32839360/
Education / Career
Article Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study.
Announcements Ann Oncol. Date of publication 2021
Co-researcher Tempero M, Oh DY, Tabernero J, Reni M, Van Cutsem E, Hendifar A, Waldschmidt DT, Starling N, Bachet JB, Chang HM, Maurel J, Garcia-Carbonero R, Lonardi S, Coussens LM, Fong L, Tsao LC, Cole G Jr, James D, Macarulla T.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33539945/
Education / Career
Article A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
Announcements Clin Transl Sci. Date of publication 2021
Co-researcher Chung TK, Lee HA, Park SI, Oh DY, Lee KW, Kim JW, Kim JH, Woo A, Lee SJ, Bang YJ, Lee H.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33382918/
Education / Career
Article Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.
Announcements Cancer Res Treat. Date of publication 2021
Co-researcher Yoo C, Oh CR, Kim ST, Bae WK, Choi HJ, Oh DY, Lee MA, Ryoo BY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33421978/
Education / Career
Article Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer.
Announcements Cancer Res Treat. Date of publication 2021
Co-researcher Yoon J, Kang SY, Lee KH, Cheon GJ, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33091966/
Education / Career
Article Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Announcements J Immunother Cancer. Date of publication 2021
Co-researcher Melisi D, Oh DY, Hollebecque A, Calvo E, Varghese A, Borazanci E, Macarulla T, Merz V, Zecchetto C, Zhao Y, Gueorguieva I, Man M, Gandhi L, Estrem ST, Benhadji KA, Lanasa MC, Avsar E, Guba SC, Garcia-Carbonero R.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33688022/
Education / Career
Article Phase II study of Avelumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib.
Announcements Clin Cancer Res. Date of publication 2021
Co-researcher Lee DW, Cho EJ, Lee JH, Yu SJ, Kim YJ, Yoon JH, Kim TY, Han SW, Oh DY, Im SA, Kim TY, Lee Y, Kim H, Lee KH.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33139266/
Education / Career
Article Prognostic Value of Serum Soluble Programmed Death-Ligand 1 and Dynamics During Chemotherapy in Advanced Gastric Cancer Patients
Announcements Cancer Res Treat. Date of publication 2021
Co-researcher Park W, Bang JH, Nam AR, Jin MH, Seo H, Kim JM, Oh KS, Kim TY, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33070562/
Education / Career
Article Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021.
Announcements J Hepatobiliary Pancreat Sci. Date of publication 2021
Co-researcher Yamamoto M, Yoshida M, Furuse J, Sano K, Ohtsuka M, Yamashita S, Beppu T, Iwashita Y, Wada K, Takako NE, Sakamoto K, Hayano K, Mori Y, Asai K, Matsuyama R, Hirashita T, Hibi T, Sakai N, Tabata T, Kawakami H, Takeda H, Mizukami T, Ozaka M, Ueno M, Naito Y, Okano N, Ueno T, Hijioka S, Shikata S, Ukai T, Strasberg S, Sarr MG, Jagannath P, Hwang TL, Han HS, Yoon YS, Wang HJ, Luo SC, Adam R, Gimenez M, Scatton O, Oh DY, Takada T.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33200538/
Education / Career
Article A phase I study of IMC-001, a PD-L1 blocker, in patients with metastatic or locally advanced solid tumors.
Announcements Invest New Drugs. Date of publication 2021
Co-researcher Keam B, Ock CY, Kim TM, Oh DY, Kang WK, Park YH, Lee J, Lee JH, Ahn YH, Kim HJ, Chang SK, Park J, Choi JY, Song YJ, Park YS.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/34268711/
Education / Career
Article Biliary tract cancer.
Announcements Lancet. Date of publication 2021
Co-researcher Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/33516341/
Education / Career
Article The prognostic role of soluble transforming growth factor-β and its correlation with soluble programmed death-ligand 1 in biliary tract cancer.
Announcements Liver Int. Date of publication 2021
Co-researcher Kim JW, Lee KH, Kim JW, Suh KJ, Nam AR, Bang JH, Jin MH, Oh KS, Kim JM, Kim TY, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32780918/
Education / Career
Article Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma.
Announcements Eur J Surg Oncol. Date of publication 2020
Co-researcher Kim BH, Kim K, Jang JY, Kwon W, Kim H, Lee KH, Oh DY, Kim H, Lee KB, Chie EK.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32782200/
Education / Career
Article Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer.
Announcements Gastric Cancer. Date of publication 2020
Co-researcher Satoh T, Kang YK, Chao Y, Ryu MH, Kato K, Cheol Chung H, Chen JS, Muro K, Ki Kang W, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Tanimoto M, Chen LT, Boku N.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31087200/
Education / Career
Article Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer.
Announcements Cancer Res Treat. Date of publication 2020
Co-researcher Kim JW, Cho SY, Chae J, Kim JW, Kim TY, Lee KW, Oh DY, Bang YJ, Im SA.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32599979/
Education / Career
Article Efficacy and Safety of Pembrolizumab for the Treatment of Advanced Biliary Cancer: Results From the KEYNOTE-158 and KEYNOTE-028 Studies.
Announcements Int J Cancer. Date of publication 2020
Co-researcher Piha-Paul SA, Oh DY, Ueno M, Malka D, Chung HC, Nagrial A, Kelley RK, Ros W, Italiano A, Nakagawa K, Rugo HS, de Braud F, Varga AI, Hansen A, Wang H, Krishnan S, Norwood KG, Doi T.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32359091/
Education / Career
Article Randomized Phase III Trial of Pegvorhyaluronidase Alfa With Nab-Paclitaxel Plus Gemcitabine for Patients With Hyaluronan-High Metastatic Pancreatic Adenocarcinoma.
Announcements J Clin Oncol. Date of publication 2020
Co-researcher Van Cutsem E, Tempero MA, Sigal D, Oh DY, Fazio N, Macarulla T, Hitre E, Hammel P, Hendifar AE, Bates SE, Li CP, Hingorani SR, de la Fouchardiere C, Kasi A, Heinemann V, Maraveyas A, Bahary N, Layos L, Sahai V, Zheng L, Lacy J, Park JO, Portales F, Oberstein P, Wu W, Chondros D, Bullock AJ; HALO 109-301 Investigators.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32706635/
Education / Career
Article Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitor.
Announcements Clin Infect Dis. Date of publication 2020
Co-researcher Keam B, Kang CK, Jun KI, Moon SM, Suh KJ, Lee DW, Ock CY, Kim M, Choi Y, Lim Y, Lee KH, Kim SH, Kim TM, Kim TY, Oh DY, Kim DW, Im SA, Lee JS, Kim ES, Kim HB, Kim NJ, Kim YJ, Park WB, Oh MD.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31680143/
Education / Career
Article Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer.
Announcements Cancer Res Treat. Date of publication 2020
Co-researcher Nam AR, Jin MH, Bang JH, Oh KS, Seo HR, Oh DY, Bang YJ.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32311864/
Education / Career
Article Ivosidenib in IDH1-mutant, Chemotherapy-Refractory Cholangiocarcinoma (ClarIDHy): A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study.
Announcements Lancet Oncol. Date of publication 2020
Co-researcher Abou-Alfa GK, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater J, Harris WP, Murphy AG, Oh DY, Whisenant J, Lowery MA, Goyal L, Shroff RT, El-Khoueiry AB, Fan B, Wu B, Chamberlain CX, Jiang L, Gliser C, Pandya SS, Valle JW, Zhu AX.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32416072/
Education / Career
Article Comparisons of Clinical Outcomes Between Weekday-Only and Full-Time, 24-Hour/7-Day Coverage Hospitalist Systems.
Announcements J Korean Med Sci. Date of publication 2020
Co-researcher Han SJ, Jung HW, Oh DY, Lee JH, Moon SD, Lee S, Yoon JH.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32383363/
Education / Career
Article Phase I Study of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Pretreated Biliary Tract Cancer.
Announcements J Immunother Cancer. Date of publication 2020
Co-researcher Yoo C, Oh DY, Choi HJ, Kudo M, Ueno M, Kondo S, Chen LT, Osada M, Helwig C, Dussault I, Ikeda M.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32461347/
Education / Career
Article Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study.
Announcements Lancet Oncol. Date of publication 2020
Co-researcher Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG, Oh DY, Dotan E, Catenacci DV, Van Cutsem E, Ji T, Lihou CF, Zhen H, F�liz L, Vogel A.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32203698/
Education / Career
Article A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data
Announcements Gastric Cancer. Date of publication 2020
Co-researcher Chen LT, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Sameshima H, Kang YK, Boku N.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31863227/
Education / Career
Article Landscape of Health-Related Quality of Life in Patients With Early-Stage Pancreatic Cancer Receiving Adjuvant or Neoadjuvant Chemotherapy: A Systematic Literature Review.
Announcements Pancreas. Date of publication 2020
Co-researcher Macarulla T, Hendifar AE, Li CP, Reni M, Riess H, Tempero MA, Dueck AC, Botteman MF, Deshpande CG, Lucas EJ, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32132518/
Education / Career
Article TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy.
Announcements Cancers (Basel). Date of publication 2020
Co-researcher Kim JW, Min A, Im SA, Jang H, Kim YJ, Kim HJ, Lee KH, Kim TY, Lee KW, Oh DY, Kim JH, Bang YJ.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32028591/
Education / Career
Article Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI-1 study.
Announcements Cancer Sci. Date of publication 2020
Co-researcher Bang YJ, Li CP, Lee KH, Chiu CF, Park JO, Shan YS, Kim JS, Chen JS, Shim HJ, Rau KM, Choi HJ, Oh DY, Belanger B, Chen LT.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31789476/
Education / Career
Article Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy.
Announcements Clin Cancer Res. Date of publication 2020
Co-researcher Sharma P, Sohn J, Shin SJ, Oh DY, Keam B, Lee HJ, Gizzi M, Kalinka E, de Vos FYFL, Ruscica D, Ferro S, Xiao F, Baverel P, Chen CC, Asubonteng K, Morsli N, Dirix L.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31801732/
Education / Career
Article The prognostic role of soluble TGF-beta and its dynamics in unresectable pancreatic cancer treated with chemotherapy.
Announcements Cancer Med. Date of publication 2020
Co-researcher Park H, Bang JH, Nam AR, Park JE, Jin MH, Bang YJ, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31701645/
Education / Career
Article HER2-targeted therapies - a role beyond breast cancer.
Announcements Nat Rev Clin Oncol. Date of publication 2020
Co-researcher Oh DY, Bang YJ.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31548601/
Education / Career
Article Therapeutic Co-targeting of WEE1 and ATM Downregulates PD-L1 Expression in Pancreatic Cancer.
Announcements Cancer Res Treat. Date of publication 2020
Co-researcher Jin MH, Nam AR, Park JE, Bang JH, Bang YJ, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31291716/
Education / Career
Article Predictive Role of Temporal Changes in Intratumoral Metabolic Heterogeneity during Palliative Chemotherapy in Patients with Advanced Pancreatic Cancer: A Prospective Cohort Study.
Announcements J Nucl Med. Date of publication 2020
Co-researcher Yoo SH, Kang SY, Cheon GJ, Oh DY, Bang YJ.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31201247/
Education / Career
Article Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial.
Announcements Future Oncol. Date of publication 2020
Co-researcher Makawita S, K Abou-Alfa G, Roychowdhury S, Sadeghi S, Borbath I, Goyal L, Cohn A, Lamarca A, Oh DY, Macarulla T, T Shroff R, Howland M, Li A, Cho T, Pande A, Javle M.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/32580579/
Education / Career
Article Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial.
Announcements J Immunother Cancer. Date of publication 2019
Co-researcher Chung HC, Arkenau HT, Lee J, Rha SY, Oh DY, Wyrwicz L, Kang YK, Lee KW, Infante JR, Lee SS, Kemeny M, Keilholz U, Melichar B, Mita A, Plummer R, Smith D, Gelb AB, Xiong H, Hong J, Chand V, Safran H.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/30717797/
Education / Career
Article Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
Announcements Ann Oncol. Date of publication 2019
Co-researcher P. Hammel, H. L. Kindler, M. Reni, E. Van Cutsem, T. Macarulla, M. J. Hall, J. O. Park, D. Hochhauser, D. Arnold, D.-Y. Oh, A. Reinacher-Schick, G. Tortora, H. Algu¨ l, E. M. O’Reilly, D. McGuinness, K. Y. Cui, S. Joo, H. K. Yoo, N. Patel & T. Golan, on behalf of the POLO Investigators
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31562758/
Education / Career
Article Pan-Pim Kinase Inhibitor AZD1208 Suppresses Tumor Growth and Synergistically Interacts with Akt Inhibition in Gastric Cancer Cells.
Announcements Cancer Res Treat. Date of publication 2019
Co-researcher Lee M, Lee KH, Min A, Kim J, Kim S, Jang H, Lim JM, Kim SH, Ha DH, Jeong WJ, Suh KJ, Yang YW, Kim TY, Oh DY, Bang YJ, Im SA,.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/29879757/
Education / Career
Article Dynamics of Soluble Programmed Death-Ligand 1 (sPDL1) during Chemotherapy and its Prognostic Implications in Cancer Patients: Biomarker Development in Immuno-Oncology.
Announcements Cancer Res Treat. Date of publication 2019
Co-researcher Ha H, Bang JH, Nam AR, Park JE, Jin MH, Bang YJ, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/30309223/
Education / Career
Article Prognostic effects of abnormal DNA damage response protein expression in breast cancer.
Announcements Breast Cancer Res Treat. Date of publication 2019
Co-researcher Suh KJ, Ryu HS, Lee KH, Kim H, Min A, Kim TY, Yang Y, Lee HB, Moon HG, Han SW, Oh DY, Han W, Park IA, Noh DY, Im SA.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/30671767/
Education / Career
Article Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer.
Announcements Cancer Res Treat. Date of publication 2019
Co-researcher Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/30282449/
Education / Career
Article Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Announcements Cancer Res Treat. Date of publication 2019
Co-researcher Nam AR, Jin MH, Park JE, Bang JH, Oh DY, Bang YJ.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/30514066/
Education / Career
Article Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients.
Announcements Breast Cancer Res Treat. Date of publication 2019
Co-researcher Kim JY, Lee DW, Lee KH, Min A, Ryu HS, Lee HB, Moon HG, Kim TY, Han SW, Oh DY, Han W, Park IA, Noh DY, Im SA, Kim S.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31028608/
Education / Career
Article Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I-III breast cancer patients.
Announcements Br J Cancer. Date of publication 2019
Co-researcher Lee DW, Ryu HS, Jin MS, Lee KH, Suh KJ, Youk J, Kim JY, Min A, Lee HB, Moon HG, Kim TY, Han SW, Oh DY, Han W, Park IA, Noh DY, Im SA.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31292534/
Education / Career
Article Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial.
Announcements JAMA Oncol. Date of publication 2019
Co-researcher O'Reilly EM, Oh DY, Dhani N, Renouf DJ, Lee MA, Sun W, Fisher G, Hezel A, Chang SC, Vlahovic G, Takahashi O, Yang Y, Fitts D, Philip PA.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31318392/
Education / Career
Article Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Announcements N Engl J Med. Date of publication 2019
Co-researcher Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Alg�l H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31157963/
Education / Career
Article Prognostic implications of soluble programmed death-ligand 1 and its dynamics during chemotherapy in unresectable pancreatic cancer.
Announcements Sci Rep. Date of publication 2019
Co-researcher Park H, Bang JH, Nam AR, Eun Park J, Hua Jin M, Bang YJ, Oh DY.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31366979/
Education / Career
Article Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors.
Announcements Ann Oncol. Date of publication 2019
Co-researcher Hellmann MD, Kim TW, Lee CB, Goh BC, Miller WH, Oh DY, Jamal R, Chee CE, Chow LQM, Gainor JF, Desai J, Solomon BJ, Das Thakur M, Pitcher B, Foster P, Hernandez G, Wongchenko MJ, Cha E, Bang YJ, Siu LL, Bendell J.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/30918950/
Education / Career
Article A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.
Announcements Oncologist. Date of publication 2019
Co-researcher Oh DY, Lee KW, Han SW, Kim JW, Shin JW, Jo SJ, Won J, Hahn S, Lee H, Kim WH, Bang YJ.
Pubmed URL https://www.ncbi.nlm.nih.gov/pubmed/31164456/

전체 메뉴

Find a Doctor

Patients

Education &
Research

Information

About SNUH

전체 검색

전체 검색